Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2024 | $37.00 | Buy | H.C. Wainwright |
| 6/11/2024 | $32.00 | Outperform | Robert W. Baird |
| 4/9/2024 | $34.00 | Buy | Mizuho |
| 3/29/2023 | $27.00 | Buy | Jefferies |
| 3/3/2023 | Outperform | TD Cowen |
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00
Robert W. Baird initiated coverage of Enliven Therapeutics with a rating of Outperform and set a new price target of $32.00
Mizuho initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $34.00
SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
Baird analyst Colleen Kusy initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating and announces Price Target of $32.
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent.
Thursday, Enliven Therapeutics Inc (NASDAQ:ELVN) released proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs). ELVN-001 is a small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML. “We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, Chief Medical Officer of Enliven. Related Co
Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions Continued to progress ELVN-002 with a focus on recently initiated combination clinical trials evaluating patients with HER2+ MBC and CRC Strong balance sheet with $292 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., Nov. 13, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small mo
BOULDER, Colo., Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 9:30 a.m. GMT. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archi
Updated Phase 1 data presented at ESH-iCMLf 26th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, pos
10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)
8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e